Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Other liabilities | 88 | — |
| Net cash used in operating activities | (184,287) | (125,885) |
| Investing activities: | ||
| Purchases of property, plant and equipment | (408) | (200) |
| Purchases of marketable securities | (996,034) | (220,055) |
| Proceeds from marketable securities | 257,922 | 337,025 |
| Net cash provided by (used in) investing activities | (738,520) | 116,770 |
| Financing activities: |
Item 1. Financial Statements
FAQ
- What is Xenon Pharmaceuticals's capex?
- Xenon Pharmaceuticals (XENE) reported capex of $275K in Q2 2026.
- How has Xenon Pharmaceuticals's capex changed year-over-year?
- Xenon Pharmaceuticals's capex increased by 75.2% year-over-year, from $157K to $275K.
- What is the long-term trend for Xenon Pharmaceuticals's capex?
- Over 4 years (2021 to 2025), Xenon Pharmaceuticals's capex has grown at a -21.0% compound annual growth rate (CAGR), from $2.05M to $799K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Xenon Pharmaceuticals's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude